A TriNetX analysis of type 2 diabetes patients saw no excess breathing complications, though a hypocalcemia signal versus SGLT2 drugs needs a closer look.
Recap by typeshit. Full story at Bioengineer.org.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
From a 600,000-veteran addiction study to fewer daily steps on smartwatches, scientists including Naveed Sattar weigh in on what GLP-1s do beyond appetite.
In data shown at the EADV Congress in Vienna, 39% of GLP-1 users reported nails lifting versus 9% of non-users. Researchers say the findings are self-reported and show association, not cause.
Loading…